Global E-Health Forum - Hamburg 2010

25-26 October 2010, Hamburg, Germany.
The Global E-Health Forum has been conceived to create a unique opportunity to discuss potential solutions in patient-centric health management. The past three Baltic Conferences on E-Health (2007-2009) have generated considerable interest in countries far beyond the Baltic Sea Region. The reason is simple: Healthcare systems all over the world are facing very similar challenges. Demographic shifts, increased burden of chronic diseases and expensive treatments as well as the impact of globalization - to mention some of the most important ones.

Therefore, organisers of Baltic Conference on E-Health have decided to found the "Global E-Health Forum". The Global E-Health Forum will replace the Baltic Conference on E-Health and is scheduled for following dates:

Global E-Health Forum - Hamburg 2010
25-26 October 2010.

Hosts of Global E-Health Forum 2010 are the European Health Telematics Association (EHTEL), the Hamburg Chamber of Commerce and IBM in cooperation with Asklepios.

Program Outline

  • October 25, 2010
    At the Hamburg Chamber of Commerce, you may expect presentations of keynote speakers from different continents, breakout sessions (workshops and as well as discussion forums) and an accompanying exhibition of solution providers. The first day will end with a reception in the U.S. Consulate General ("the little White House at the lake Alster").
  • October 26, 2010
    The program at Asklepios clinics will offer presentations, guided tours and show cases of solution providers and a panel discussion.

If you are interested in the sponsorship opportunities (platinum sponsor, premium sponsor and sponsor/workshop) or in exhibiting at the Global E-Health Forum on October 25 in the Hamburg Chamber of Commerce, please explore:

Register now to benefit from early bird fee of Euro 299 incl. VAT. Regular fee will be Euro 399 incl. VAT. The fee includes the admission to all conference sessions, lunches, coffee breaks and the evening reception on October 25.

For further information and registration, please visit:
http://www.global-ehealth-forum.com

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...